ANTX insider trading
NasdaqGS HealthcareAN2 Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Company website: www.an2therapeutics.com
ANTX insider activity at a glance
FilingIQ has scored 277 insider transactions for ANTX since Mar 29, 2022. The most recent filing in our index is dated Mar 19, 2026.
Across the full history, 37 open-market purchases
and 92 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ANTX insider trades is 54.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ANTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ANTX?
- FilingIQ tracks 277 Form 4 insider transactions for ANTX (AN2 Therapeutics, Inc.), covering filings from Mar 29, 2022 onwards. 84 of those were filed in the last 90 days.
- Are ANTX insiders net buyers or net sellers?
- Across the full Form 4 history for ANTX, 37 transactions (13%) were open-market purchases and 92 (33%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ANTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ANTX in?
- AN2 Therapeutics, Inc. (ANTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $28.77M.
Methodology & sources
Every ANTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.